Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab for prevention of cardiac allograft vasculopathy after heart transplantation
2017-005097-19Phase 4Completed
- Sponsor
- Oslo University Hospital
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of evolocumab in coronary vasculopathy (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Baseline-adjusted maximal intimal thickness at 12 months. Started Sep 2018; status: completed.
02
Drugs
evolocumab
03
Conditions
coronary vasculopathy
Beyond the preview
Go deeper on 2017-005097-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005097-19.